Scarica l'app Stockscreener
7.62
2.83%
0.21
Dopo l'orario di chiusura:
7.71
0.09
+1.18%
Regenxbio Inc Borsa (RGNX) Ultime notizie
Stifel Financial Corp Boosts Position in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 4,880 Shares of REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
REGENXBIO to Participate in Upcoming Investor Conferences - Kilgore News Herald
BNP Paribas Financial Markets Purchases 17,533 Shares of REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
Trading (RGNX) With Integrated Risk Controls - Stock Traders Daily
REGENXBIO: A Hidden Gem in Gene Therapy with Promising Pipeline and Growth Potential - mediahousepress
REGENXBIO's SWOT analysis: gene therapy firm's stock poised for growth By Investing.com - Investing.com Australia
REGENXBIO's SWOT analysis: gene therapy firm's stock poised for growth - Investing.com India
National Bank of Canada FI Invests $713,000 in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat
Regenxbio stock hits 52-week low at $8.39 amid market challenges - Investing.com Australia
REGENXBIO Inc. (NASDAQ:RGNX) Shares Bought by Charles Schwab Investment Management Inc. - Defense World
Royal Bank of Canada Reiterates “Outperform” Rating for REGENXBIO (NASDAQ:RGNX) - Defense World
REGENXBIO Inc. (NASDAQ:RGNX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Where Regenxbio Stands With Analysts - Benzinga
Jacobs Levy Equity Management Inc. Trims Position in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat
REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights - The Eastern Progress Online
REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect - The Eastern Progress Online
Regenxbio stock touches 52-week low at $8.51 amid market challenges - Investing.com Canada
(RGNX) Trading Report - Stock Traders Daily
Regenxbio Updates Leadership, Names New CEO - Contract Pharma
REGENXBIO Inc. (NASDAQ:RGNX) is Redmile Group LLC's 10th Largest Position - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Makes New Investment in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat
REGENXBIO's SWOT analysis: gene therapy stock poised for growth amid challenges - Investing.com India
How To Trade (RGNX) - Stock Traders Daily
HC Wainwright Cuts REGENXBIO (NASDAQ:RGNX) Price Target to $36.00 - Defense World
REGENXBIO (NASDAQ:RGNX) Given Buy Rating at Chardan Capital - Defense World
Regenxbio price target lowered to $36 from $40 at H.C. Wainwright - MSN
HC Wainwright Has Lowered Expectations for REGENXBIO (NASDAQ:RGNX) Stock Price - MarketBeat
Regenxbio starts pivotal trial testing DMD gene therapy RGX-202 - Muscular Dystrophy News
Leerink Partnrs Increases Earnings Estimates for REGENXBIO - MarketBeat
H.C. Wainwright sees 45% approval probability for RGX-202, reiterates Buy on Regenxbio stock - Investing.com Nigeria
H.C. Wainwright sees 45% approval probability for RGX-202, reiterates Buy on Regenxbio stock By Investing.com - Investing.com South Africa
Chardan Capital Reaffirms Buy Rating for REGENXBIO (NASDAQ:RGNX) - MarketBeat
Regenxbio down 13% ahead of data readout for muscular dystrophy asset - MSN
Regenxbio surges 10% as it launches pivotal phase of muscular dystrophy asset trial - MSN
Regenxbio eyes 2026 filing for Duchenne muscular dystrophy gene therapy - Pharmaceutical Technology
US Bancorp DE Has $26,000 Stake in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
Morgan Stanley Reiterates “Overweight” Rating for REGENXBIO (NASDAQ:RGNX) - Defense World
Raymond James maintains $18 target on RGNX after trial data - Investing.com
Regenxbio Sets Sights On 2026 Filing For DMD Gene Therapy - Citeline
FDA endorses speedy approval path for Regenxbio Duchenne gene therapy - BioPharma Dive
Raymond James maintains $18 target on RGNX after trial data By Investing.com - Investing.com UK
REGENXBIO (NASDAQ:RGNX) Sees Strong Trading VolumeTime to Buy? - MarketBeat
What's Going On With REGENXBIO Shares Monday? - Benzinga
Regenxbio Share Surge 20% on Duchenne Muscular Dystrophy Treatment Trial Data, Expansion - MarketWatch
Regenxbio (RGNX) Initiates Pivotal Phase Of Affinity Duchenne® Trial Of Rgx-202 Gene Therapy And Reports Positive Functional Data - StreetInsider.com
REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA - PR Newswire
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):